Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study In Patients With Dyslipidaemia

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: December 9, 2005
Last updated: August 27, 2009
Last verified: August 2009
Study in patients with dyslipidaemia.

Condition Intervention Phase
Drug: GW677954
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomised,Double-blind, Parallel Group, Placebo-controlled, Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of Oral GW677954 Capsules 2.5mg, 5mg, 10mg and 20mg a Day for 24 Weeks in Overweight Dyslipidaemic Subjects

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Percentage change from baseline in non-HDL-C based on log-transformed data at week 24.

Secondary Outcome Measures:
  • Percentage change from baseline in lipids, in Homeostasis Model Assessment-insulin sensitivity (HOMA-S), C-Reactive Protein (CRP), Fasting Plasma Glucose (FPG), body weight and waist circumference.

Estimated Enrollment: 290
Study Start Date: December 2005

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Waist circumference =102cm (men) or =88cm (women) at visit 1.
  • Fasting plasma HDL C =40mg/dL (1.03mmol/L) (men) or =50mg/dL (1.29mmol/L) (women) at Screening Visit 1.
  • Fasting TGs =150mg/dL (1.69mmol/L) and =800mg/dL (8.96mmol/L) at Screening Visit 1.
  • Subjects whose plasma LDL C concentration does not require treatment according to the NCEP ATP III guidelines at Screening Visit 1.

Exclusion Criteria:

  • History of diabetes
  • History of cardiovascular disease
  • Diagnosis of genetic lipid disorders
  • History of muscle pain
  • History of cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00264667

  Show 49 Study Locations
Sponsors and Collaborators
Study Director: GSK Clinical Trials, MA GlaxoSmithKline
  More Information

Responsible Party: Study Director, GSK Identifier: NCT00264667     History of Changes
Other Study ID Numbers: ADG103440 
Study First Received: December 9, 2005
Last Updated: August 27, 2009
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by GlaxoSmithKline:

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases processed this record on October 27, 2016